STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a
Fidel Strub was 3 years old when his face began rotting away. “It’s hell. It’s like you have a burning face,” he told me. “You
Welcome to TDR’s review of the Top 5 Psychedelic Developments for the week of December 11. Aside from presenting a synopsis of events, we provide
Merck’s Welireg won a label expansion on Thursday in a common form of kidney cancer, weeks ahead of its decision date and without a clear
The FDA on Friday granted full approval to Seagen and Astellas Pharma’s Padcev (enfortumab vedotin-ejfv) in combo with Merck’s Keytruda (pembrolizumab) for patients with locally
In the past five years, AbbVie rebuilt a middle school in Chicago, opened the doors to a new family center at St. Jude Children’s Research
Following FDA approval, Vertex Pharmaceuticals and CRISPR Therapeutics on Friday received a positive recommendation for a conditional approval by a key European medicines panel for
Biologics developers are protecting their most lucrative assets with a particular type of patent that they can quickly pile up and drive costly litigation around,
AC Immune’s anti-pTau drug enters PhIIb: The Swiss biotech’s partner Johnson & Johnson launched the “potentially registration-enabling” study of ACI-35.030 in people with preclinical Alzheimer’s
Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman